TP53 and cancer: MI-219 is a specific, orally active, low molecular weight inhibitor, that binds to the p53 binding pocket of MDM2 and disrupts the MDM2-p53 interaction leading to apoptosis via reactivating wt-p53 in wt-p53 cancer cells [27,28].